Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-guided dosing of desmopressin and VWF-containing concentrates in von Willebrand disease
2018-001631-46Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Feb 2019
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of desmopressin and vonicog alfa in von Willebrand disease (VWD) (2 arms), sponsored by Erasmus MC. Primary endpoint: Predictive performance of DDAVP population PK model. Started Feb 2019; status: active.
02
Drugs
desmopressinvonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2018-001631-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001631-46.